首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   2700篇
  免费   577篇
  国内免费   28篇
耳鼻咽喉   38篇
儿科学   61篇
妇产科学   81篇
基础医学   342篇
口腔科学   80篇
临床医学   274篇
内科学   627篇
皮肤病学   73篇
神经病学   191篇
特种医学   122篇
外科学   432篇
综合类   126篇
一般理论   2篇
预防医学   189篇
眼科学   72篇
药学   194篇
中国医学   31篇
肿瘤学   370篇
  2023年   18篇
  2022年   15篇
  2021年   97篇
  2020年   102篇
  2019年   144篇
  2018年   136篇
  2017年   148篇
  2016年   139篇
  2015年   188篇
  2014年   179篇
  2013年   207篇
  2012年   167篇
  2011年   166篇
  2010年   150篇
  2009年   143篇
  2008年   125篇
  2007年   121篇
  2006年   105篇
  2005年   99篇
  2004年   92篇
  2003年   74篇
  2002年   74篇
  2001年   58篇
  2000年   45篇
  1999年   37篇
  1998年   36篇
  1997年   24篇
  1996年   21篇
  1995年   21篇
  1994年   27篇
  1993年   32篇
  1992年   17篇
  1991年   25篇
  1990年   23篇
  1989年   17篇
  1988年   18篇
  1987年   22篇
  1986年   19篇
  1985年   25篇
  1984年   18篇
  1983年   16篇
  1982年   10篇
  1981年   8篇
  1979年   10篇
  1978年   9篇
  1977年   8篇
  1974年   13篇
  1973年   7篇
  1972年   7篇
  1971年   17篇
排序方式: 共有3305条查询结果,搜索用时 16 毫秒
1.
2.
3.
4.
5.
6.
7.

Background

Muscle invasive bladder cancer (MIBC) is prevalent in the older patients, who are a vulnerable population with multiple co-morbidities and at increased risk of complications. Radical cystectomy is often not suitable, hence radical radiotherapy (RT) is an alternative option. We reviewed the outcomes of older patients treated with RT with or without concurrent chemotherapy (CRT) at our institution.

Methods

We retrospectively reviewed patients aged 65?years and above treated with radical RT for MIBC at our institution between March 2002 to January 2017. Data was collected from institutional medical records and RT databases. The primary outcome was 2- and 5-year overall survival (OS), recurrence free survival (RFS), and toxicities. Univariate cox proportional hazard regression models were performed to identify independent factors with significant impact on survival.

Results

We identified 45 patients (34 males, 11 females) with a median age of 77?years (range 65–95). All patients received maximal transurethral resection of the bladder tumour prior to RT. Median dose of total RT was 64?Gy (range 50–69.8?Gy). Twenty one patients (47%) received CRT. Planned treatment was completed in 42 (93.3%) patients. Median follow-up was 31?months (range 1–147?months). The 2- and 5-year OS was 64% and 44%, respectively. The 2- and 5-year RFS was 68% and 49%, respectively. Median RFS was 34?months (range 8–121?months). Median OS was 56?months (range 18–100?months). Univariate analysis showed that performance status (0–1 vs. 2–3; HR 2.7, 95% CI 1.07–6.8, p?=?0.035) and International Society of Geriatric Oncology (SIOG) group (≤2 vs. >2; HR 3.23, 95% CI 1.12–8.64, p?=?0.019) were significantly associated with increased hazard for death. One patient (2%) had grade 3 cystitis.

Conclusion

Radical RT is well tolerated in older patients with MIBC. We report outcomes similar to published data. Older patients should be considered for curative treatment despite their age. However, careful selection is warranted as frail patients (PS ≥2; SIOG >2) may benefit less.  相似文献   
8.
9.

Background

Rosacea is a chronic inflammatory skin condition whose etiology has been linked to mast cells and the antimicrobial peptide cathelicidin LL-37. Individuals with refractory disease have demonstrated clinical benefit with periodic injections of onabotulinum toxin, but the mechanism of action is unknown.

Objectives

To investigate the molecular mechanism by which botulinum toxin improves rosacea lesions.

Methods

Primary human and murine mast cells were pretreated with onabotulinum toxin A or B or control. Mast cell degranulation was evaluated by β-hexosaminidase activity. Expression of botulinum toxin receptor Sv2 was measured by qPCR. The presence of SNAP-25 and VAMP2 was established by immunofluorescence. In vivo rosacea model was established by intradermally injecting LL-37 with or without onabotulinum toxin A pretreatment. Mast cell degranulation was assessed in vivo by histologic counts. Rosacea biomarkers were analyzed by qPCR of mouse skin sections.

Results

Onabotulinum toxin A and B inhibited compound 48/80-induced degranulation of both human and murine mast cells. Expression of Sv2 was established in mouse mast cells. Onabotulinum toxin A and B increased cleaved SNAP-25 and decreased VAMP2 staining in mast cells respectively. In mice, injection of onabotulinum toxin A significantly reduced LL-37-induced skin erythema, mast cell degranulation, and mRNA expression of rosacea biomarkers.

Conclusions

These findings suggest that onabotulinum toxin reduces rosacea-associated skin inflammation by directly inhibiting mast cell degranulation. Periodic applications of onabotulinum toxin may be an effective therapy for refractory rosacea and deserves further study.  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号